Print

VRC 605

VRC 605: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

Trial Details:

I Ongoing
National Institute of Allergy and Infectious Diseases (NIAID) December 01, 2016
VRC-HIVMAB075-00-AB VRC07-523LS antibody
VRC-HIVMAB075-00-AB Passive Immunization
USA 40
NCT03015181
https://www.clinicaltrials.gov/ct2/show/NCT03015181